scholarly journals Initial Report of a Cutaneous T-Cell Lymphoma Appearing on the Auricular Helix

2000 ◽  
Vol 79 (5) ◽  
pp. 391-396 ◽  
Author(s):  
Brian J. Baumgartner ◽  
Vincent Eusterman ◽  
Jerome Myers ◽  
Phillip Massengill
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Skin Lesions ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Initial Report ◽  
Delay In Diagnosis ◽  
Multiple Biopsies ◽  
Key Factor ◽  
High Index Of Suspicion

We report a case of cutaneous T-cell lymphoma in which the first sign of disease was involvement of the superior auricular helix. A review of the literature reveals that T-cell lymphoma often presents cutaneously, but it usually does not involve the ear, and an auricular lesion is rarely the first sign. The uncommon nature of this presentation, in addition to the potential need for multiple biopsies for a tissue diagnosis, can lead to a delay in diagnosis. When evaluating skin lesions in the head and neck, a high index of suspicion for cutaneous T-cell lymphoma is a key factor in its early diagnosis.

Primary cutaneous aggressive epidermotropic CD8 positive cytotoxic T-cell lymphoma of the ear

2006 ◽  
Vol 121 (5) ◽  
pp. 503-505 ◽  
Author(s):  
Z Fika ◽  
P D Karkos ◽  
K Badran ◽  
R E Williams
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cytotoxic T Cell ◽  
Cutaneous T Cell Lymphoma ◽  
Cutaneous Lesions ◽  
T Cell Lymphomas ◽  
Uncommon Presentation ◽  
Multiple Biopsies ◽  
High Index Of Suspicion

We report a case of an epidermotropic CD8+ cutaneous T-cell lymphoma which initially presented as an ulcerated lesion of the pinna. Although T-cell lymphomas may present as cutaneous lesions, the ear is rarely involved. This uncommon presentation and the need for multiple biopsies means that the diagnosis of these lesions may be delayed or missed. A high index of suspicion is required when evaluating cutaneous lesions in the head and neck area.

Interleukin-7 and interleukin-15 regulate the expression of thebcl-2 and c-myb genes in cutaneous T-cell lymphoma cells

Blood ◽  
2001 ◽  
Vol 98 (9) ◽  
pp. 2778-2783 ◽  
Author(s):  
Jian-Zhong Qin ◽  
Chun-Lei Zhang ◽  
Jivko Kamarashev ◽  
Reinhard Dummer ◽  
Günter Burg ◽  
...  
Keyword(s):  
Cell Death ◽  
T Cell ◽  
Cell Lymphoma ◽  
Skin Lesions ◽  
Test System ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Interleukin 7 ◽  
Survival Gene ◽  
Myb Genes

Abstract Interleukin-7 (IL-7) and IL-15 have been recently identified as growth factors for cutaneous T-cell lymphoma (CTCL) cells, and they protect these cells from cell death. Using the CTCL cell line SeAx as a test system now shows that IL-7 and IL-15 are indeed necessary to maintain high levels of bcl-2. The up-regulation of bcl-2 was paralleled by increased DNA-binding activities of the transcription factors STAT2, STAT5, STAT6, and c-Myb to bcl-2gene promoter–enhancer elements. Because STAT5 and c-Myb positively regulate bcl-2, IL-7 and IL-15 may mediate some of their effects on cell death survival gene expression through these 2 factors. Constitutive activities of the 3 STAT factors and c-Myb were found in the IL-7– and IL-15–independent CTCL cell lines HUT78 and MyLa 2059. The c-Myb protein was also present in CTCL cells of the skin lesions of all investigated patients. These results indicate that IL-7 and IL-15 may increase bcl-2 expression in CTCL cells by the activation of c-myb and STAT factors.

scholarly journals Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Kimberly Aderhold ◽  
Lisa Carpenter ◽  
Krysta Brown ◽  
Anthony Donato
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Rapid Progression ◽  
Entire Body ◽  
Cutaneous T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Multiple Biopsies ◽  
Skin Conditions

Primary Cutaneous Peripheral T-Cell Lymphoma NOS (PTL-NOS) is a rare, progressive, fatal dermatologic disease that presents with features similar to many common benign plaque-like skin conditions, making recognition of its distinguishing features critical for early diagnosis and treatment (Bolognia et al., 2008). A 78-year-old woman presented to ambulatory care with a single 5 cm nodule on her shoulder that had developed rapidly over 1-2 weeks. Examination was suspicious for malignancy and a biopsy was performed. Biopsy results demonstrated CD4 positivity, consistent with Mycosis Fungoides with coexpression of CD5, CD47, and CD7. Within three months her cancer had progressed into diffuse lesions spanning her entire body. As rapid progression is usually uncharacteristic of Mycosis Fungoides, her diagnosis was amended to PTL-NOS. Cutaneous T-Cell Lymphoma (CTCL) should be suspected in patients with patches, plaques, erythroderma, or papules that persist or multiply despite conservative treatment. Singular biopsies are often nondiagnostic, requiring a high degree of suspicion if there is deviation from the anticipated clinical course. Multiple biopsies are often necessary to make the diagnosis. Physicians caring for patients with rapidly progressive, nonspecific dermatoses with features described above should keep more uncommon forms of CTCL in mind and refer for early biopsy.

scholarly journals A Case of Cutaneous T-Cell Lymphoma with Nodular Skin Lesions, Third Nerve Palsy and Peripheral Vascular Disease: Can It Be a Case of Angiocentric Lymphoma?

2016 ◽  
Vol 6 (1) ◽  
pp. 40-42
Author(s):  
Mohammad Ferdous Ur Rahaman ◽  
Mohammad Mainul Hasan Chowdhury ◽  
AKM Motiur Rahman Bhuiyan ◽  
MA Jalil Chowdhury
Keyword(s):  
T Cell ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Nerve Palsy ◽  
Cell Lymphoma ◽  
Skin Lesions ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Peripheral Vascular ◽  
Angiocentric Lymphoma

Angiocentric lymphoma is a subtype of cutaneous T-cell lymphoma, characterized by occlusion of vessels by lymphoid infiltrate. Here, we report a case of biopsy confirmed cutaneous T-cell lymphoma who presented with third cranial nerve palsy, peripheral vascular disease and nodular skin lesions in the right thigh. All these findings of this case can be explained by mechanism of vascular infiltration and tissue destruction in angiocentric lymphoma which is a rare disorder.Birdem Med J 2016; 6(1): 40-42

Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2466-2466 ◽  
Author(s):  
Navneet Dhillon ◽  
Srinivasa Bakkannagari ◽  
Chaan Ng ◽  
Joann Lim ◽  
Madeline Duvic ◽  
...  
Keyword(s):  
T Cell ◽  
Dose Level ◽  
Liposomal Doxorubicin ◽  
Cell Lymphoma ◽  
Phase 1 ◽  
Skin Lesions ◽  
T Cell Lymphoma ◽  
Dose Finding ◽  
Cutaneous T Cell Lymphoma ◽  
Heavily Pretreated

Abstract BACKGROUND: There is preclinical data suggesting pro-apoptotic synergy between the proteosome inhibitor bortezomib, doxorubucin and gemcitabine. Therefore, we are currently conducting a Phase I dose finding trial of this combination. As a part of this trial, high response rates with excellent tolerance were noted in advanced cutaneous T- cell lymphoma, and are presented here. METHODS: A 3+ 3 design was used. There were two cohorts of patients: < 65 and ≥65 years of age. The older cohort was dose escalated after the younger cohort demonstrated safety at a dose level. Initial dose escalations were in bortezomib alone, followed by gemcitabine, and then by liposomal doxorubicin. RESULTS: There were 33 patients who were treated on this trial to date. We are reporting the results of 7 patients with cutaneous T cell lymphoma. These patients had been heavily pretreated with a median of 6 prior therapies (range 1–12). All six of six evaluable patients (100%) achieved a partial remission (PR). Some of these responses are ongoing and the patients are still improving. The most common toxicities were grade 2 thrombocytopenia (50% of patients), grade 1–2 fatigue (44% patients), grade1–2 mucositis (14% patients), and myelosuppression (12% patients). Four patients needed hospitalization early in the course for sepsis. All of these patients had advanced disease with ulcerating skin lesions. Dose limiting toxicity has not been seen. CONCLUSIONS: The above combination is safe up to the doses tested so far- (dose level 5 = doxil 24mg/m2 on day1, gemcitabine 800 mg/m2 on days 1 and 8 and bortezomib 1.0 mg/m2 on days 1,4,8,11) and has activity in heavily pretreated, advanced cutaneous T-Cell lymphoma. Responses in Cutaneous T Cell Lymphoma Age Sex Stage Number of prior therapies Dose Level Response Duration of therapy in months 71 F IV 12 1 PR 4 32 F IV 6 1 PR 3 (sent to BMT) 61 F IV 8 2 Lost to follow up after 2 doses 72 M IV 2 2 PR 7+ 73 M IV B 6 2 PR 4+ 53 M II B 1 5 PR 7+ 60 F IV 5 5 PR 8+

Mycosis-fungoides-Type Cutaneous T Cell Lymphoma of the Hands and Soles: A Variant Causing Delay in Diagnosis and Adequate Treatment of Patients with Palmoplantar Eczema

Dermatology ◽  
2002 ◽  
Vol 205 (3) ◽  
pp. 239-244 ◽  
Author(s):  
Konstanze Spieth ◽  
Marcella Grundmann-Kollmann ◽  
Ulf Runne ◽  
Gyde Staib ◽  
Christian Fellbaum ◽  
...  
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Adequate Treatment ◽  
Delay In Diagnosis

scholarly journals Angioimmunoblastic T Cell Lymphoma Mimicking Chronic Urticaria

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Mohleen Kang ◽  
Nitasha Bhatia ◽  
Adrienne Sauder ◽  
Mirela Feurdean
Keyword(s):  
T Cell ◽  
Primary Care Physicians ◽  
Cell Lymphoma ◽  
Distinct Type ◽  
Maculopapular Rash ◽  
Skin Lesions ◽  
T Cell Lymphoma ◽  
Cutaneous Manifestations ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
High Index Of Suspicion

Angioimmunoblastic T cell lymphoma (AITL) is a rare but distinct type of T cell lymphoma with an aggressive course and high mortality. Most patients are diagnosed late in the disease and usually present with generalized lymphadenopathy. A minority have skin lesions at the time of diagnosis, more commonly in the form of nonspecific maculopapular rash with or without pruritus. We report a rare case of AITL presenting with chronic, recurrent angioedema and urticaria-like lesions and no palpable peripheral adenopathy. Primary Care physicians, dermatologists, and allergists must maintain a high index of suspicion for cutaneous manifestations of lymphoma, especially if the skin lesions are refractory to standard treatment. Timely diagnosis is essential to improve survival.

scholarly journals Frequency and Survival of T-Cell Lymphomas in Peru: Initial Report of a Peruvian Registry Experience

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1374-1374
Author(s):  
Daniel J Enriquez ◽  
Jhoisy Casas ◽  
Gustavo Sandival ◽  
Johan Espino ◽  
Evelyn Espinoza-Morales ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cell ◽  
Latin American ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
World Health ◽  
Type I ◽  
Cutaneous T Cell Lymphoma ◽  
Initial Report ◽  
T Cell Lymphomas

Abstract Introduction: T-cell lymphomas are a relatively rare and heterogeneous group of lymphoid neoplasms. Its incidence relies on viral infections incidence as Human T-cell lymphotropic virus type I-II (HTLV-I/II) and Ebstein Bar virus (EBV). Specifically, these viruses have a significantly higher incidence in Latin-American populations. Our objective was to calculate the incidence and survival of T-cell lymphomas in the largest Peruvian population based on a national registry. Methods: We conducted a multicenter, retrospective registry study of non-Hodgkin T cell lymphoma. The data was extracted from Instituto Nacional de Enfermedades Neoplasicas and Oncosalud-AUNA, Lima-Peru, from January 2010 to December 2019, a total of 948 patients who were diagnosed as mature T cell non-Hodgkin lymphoma based on the World Health Organization Classification 2008 were enrolled. T-lymphoblastic lymphoma/leukemia was excluded. Overall survival was calculated based on death dates from the Peruvian national identification registry (RENIEC). Results: The median age was 51 years (range, 1-94), and male and female patients were 512 (54%) and 436 (46%). Among the 948 patients enrolled, Peripheral T-cell lymphoma was the common neoplasm accounting for 23% (n=221), and Extra-Nodal NK T-lymphoma (22%, n=213), Adult T-cell lymphoma (22%, n=205), Anaplasic Large cell lymphoma (14%, n=131), Cutaneous T-cell lymphoma (14%, n=129) (Figure 1a). At the time of diagnosis, extranodal disease was found in 68.6% (650) of patients. By July 2021, only 15.3% of cases were in remission and 37% (350) were alive. Median global overall survival of T-cell lymphomas was 1 year (0.8-1.1), Cutaneous T-cell lymphoma had the highest survival and Adult T-cell lymphoma had the lowest survival (Table 1 and Figure 1b). Conclusion: This initial report shows a relatively high frequency of mature T-cell lymphomas in Latin-America real-world setting, and confirms that T-cell lymphomas patients had a dismal outcome. The clinical outcome for patients with T-cell lymphomas subtypes is poor with standard therapies, and novel agents and new modalities are needed to improve survival. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document